HEPALINK - Announcement of Resolutions of the 20th Meeting of the 6th Board of Directors of Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. (Shenzhen HEPALINK Pharmaceutical Group Co., Ltd.)

(a joint stock limited company incorporated in the People's Republic of China)

(Stock code: 9989)

Overseas regulatory announcement

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "Company") in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The announcement published by the Company on the Shenzhen Stock Exchange website is set out below for reference only.

By order of the board of directors

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Li Li

Chairman

Shenzhen, China, March 30, 2026

As of the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; the independent non-executive directors of the Company are Mr. Huang Peng, Mr. Yi Ming and Mr. Pu Hong.

Securities code: 002399 Securities abbreviation: Hepalink Announcement Number: 2026-002 Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Announcement of Resolutions of the 20th Meeting of the Sixth Board of Directors

The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.

1. Convening of board of directors meetings

The notice and resolutions of the 20th meeting (hereinafter referred to as the "meeting") of the sixth session of the board of directors of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") were issued by email on March 16, 2026. The meeting was held at 14:00 on March 30, 2026 in the conference room at No. 21 Langshan Road, Songpingshan, Nanshan District, Shenzhen, by a combination of on-site and communication methods. There were 7 directors who should participate in the voting at this meeting, and 7 directors actually participated in the voting. Among them, Mr. Zhang Ping participated in the voting through communication. The company's senior managers attended the meeting, which was chaired by Mr. Li Li, chairman of the company. The notice, convening of this meeting and the number of directors participating in the voting were in compliance with relevant laws and regulations and the relevant provisions of the Articles of Association.

2. Review status of board of directors meeting

The following proposals were carefully considered and approved by the directors present at the meeting:

1. "2025 Board of Directors Work Report"

Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.

For details, please refer to "Section 3 Management Discussion and Analysis" and "Section 4 Corporate Governance, Environment and Society" in the "2025 Annual Report" disclosed by the company on the cninfo.com.cn on the same day.

The company's independent directors Huang Peng, Yi Ming, Pu Hong and Lu Chuan (retired) submitted the "2025 Independent Directors' Work Report" to the board of directors and will take office at the company's 2025 annual shareholders' meeting. The current independent directors submitted the "Independent Directors' Self-examination Report on Independence" to the company's board of directors. The company's board of directors evaluated this and issued the "Special Opinions of the Board of Directors on the Independence Assessment of Independent Directors in 2025."

For details, please refer to the "2025 Independent Directors' Work Report" and "The Board of Directors' Special Opinions on the 2025 Independent Directors' Independence Assessment" disclosed by the company on the cninfo website www.cninfo.com.cn on the same day.

This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.

2. "2025 General Manager Work Report"

Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.

The general manager reported to the board of directors on the company's operating conditions in 2025 and the work plan for 2026, which was reviewed and approved by the board of directors.

3. "2025 Annual Report" and its summary, H-share "2025 Results Announcement", H-share "2025 Annual Report" and "2025 Corporate Governance Report"

Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.

For details, please refer to the company's "2025 Annual Report" disclosed on the cninfo.com.cn on the same day; disclosed on the same day in "Securities Times", "China Securities News", "Shanghai Securities News", "Securities Daily" and cninfo.com www.cnin fo.com.cn's "2025 Annual Report Summary"; and the H-share "2025 Results Announcement" disclosed on the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk and the company's website at www.hepalink.com on the same day.

The company prepared the H-share "2025 Annual Report" and the H-share "2025 Corporate Governance Report" in accordance with the provisions of the Hong Kong Stock Exchange Listing Rules, and agreed to authorize the joint company secretary to approve the external disclosure of the H-share "2025 Annual Report" and "2025 Corporate Governance Report" after the review is completed, and publish them on the website of the Hong Kong Stock Exchange within the time limit specified by the Hong Kong Stock Exchange and send them to H-share shareholders.

This proposal has been unanimously approved at the 13th meeting of the Audit Committee of the sixth session of the Board of Directors of the company. 4. "Profit Distribution Plan for 2025"

The company's profit distribution plan for 2025 is: based on the total share capital of 1,467,296,204 shares at the end of 2025, a cash dividend of 1.45 yuan (tax included) will be distributed for every 10 shares, with a total cash dividend of 212,757,949.58 yuan, and the remaining profits will be retained as undistributed profits. No bonus shares will be issued, and no capital reserve will be converted into capital.

Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.

For details, please refer to the "Announcement on the 2025 Profit Distribution Plan" disclosed by the company in the Securities Times, China Securities Journal, Shanghai Securities News, Securities Daily and www.cninfo.com.cn on the same day.

This proposal has been unanimously approved at the 13th meeting of the Audit Committee of the sixth session of the Board of Directors of the company. This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.

5. "Proposal on Confirmation of Directors' 2025 Remuneration and 2026 Remuneration Plan"

Voting results: 0 votes in favor, 0 abstentions, and 0 votes against. (All directors abstained from voting)

For details of the company's directors' remuneration in 2025, please refer to the relevant content in "Section 4 Corporate Governance, Environment and Society" in the company's "2025 Annual Report" disclosed on the cninfo.com www.cninfo.com.cn on the same day. The remuneration plan for directors in 2026 is:

The remuneration of non-independent directors (including employee representative directors) who hold management functions in the company will be determined in accordance with the "Articles of Association", "Remuneration and Assessment System for Directors and Senior Management Personnel" and other relevant regulations as well as the annual operating performance assessment, including basic salary, performance remuneration and statutory social security benefits.

Independent directors receive remuneration based on the work allowance standards for independent directors approved by the shareholders' meeting. The expenses incurred by independent directors in performing their duties shall be reimbursed by the company according to the facts.

This proposal has been reviewed at the fifth meeting of the Remuneration and Appraisal Committee of the sixth session of the Board of Directors of the Company. All members abstained from voting. This proposal is directly submitted to the Company's Board of Directors for review. All directors of the company abstained from voting on this proposal, which will be directly submitted to the company's 2025 annual shareholders' meeting for review.

6. The voting results of "Proposal on Confirming the 2025 Remuneration and 2026 Remuneration Plan for Senior Management Personnel": 5 votes in favor, 0 abstentions, and 0 votes against. (Related directors Ms. Li Tan and Mr. Shan Yu abstained from voting)

For details on the remuneration of the company's senior managers in 2025, please refer to the relevant content of "Section 4 Corporate Governance, Environment and Society" in the "2025 Annual Report" disclosed by the company on the cninfo website www.cninfo.com.cn on the same day. The salary plan for senior management personnel in 2026 is:

The company's senior managers receive remuneration based on their specific management positions in the company, in accordance with the Articles of Association, the Remuneration and Assessment System for Directors and Senior Management and other relevant regulations, based on actual operating performance and completion of personal performance responsibility targets.

This proposal has been unanimously approved at the fifth meeting of the Remuneration and Appraisal Committee of the sixth session of the Board of Directors of the Company. The remuneration situation of the company's senior managers in 2025 will be reported to the company's shareholders' meeting.

7. "2025 Internal Control Evaluation Report"

Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.

For details, please refer to the "2025 Internal Control Evaluation Report" disclosed by the company on the cninfo website www.cninfo.com.cn on the same day.

This proposal has been unanimously approved at the 13th meeting of the Audit Committee of the sixth session of the Board of Directors of the company. 8. "Proposal on using own funds to purchase financial products and conduct cash management"

Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.

For details, please refer to the "Announcement on the Use of Own Funds to Purchase Wealth Management Products and Conduct Cash Management" disclosed by the company on the same day in Securities Times, China Securities Journal, Shanghai Securities News, Securities Daily and www.cninfo.com.cn.

This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.

9. "Proposal on Carrying out Foreign Exchange Derivatives Transactions for the Purpose of Hedging"

Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.

For details, please refer to the "Announcement on Carrying out Foreign Exchange Derivatives Transactions for the Purpose of Hedging" disclosed by the company on the same day in "Securities Times", "China Securities Journal", "Shanghai Securities News", "Securities Daily" and www.cninfo.com.cn. For relevant feasibility analysis, please refer to the "Feasibility Analysis Report on Carrying out Foreign Exchange Derivatives Transactions for the Purpose of Hedging" disclosed on the same day on the Juchao Information Network www.cninfo.com.cn.

This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.

10. "Proposal on Applying for Credit Lines from Banks and Providing Guarantees in 2026"

Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.

For details, please refer to the "Announcement on Applying for Credit Lines from Banks and Providing Guarantees in 2026" disclosed by the company on the same day in Securities Times, China Securities Journal, Shanghai Securities News, Securities Daily and www.cninfo.com.cn.

This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.

11. "Proposal on Changing the Use of Funds Raised by H Shares"

Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.

For details, please refer to the "Announcement on Changes in the Use of H-Share Raised Funds" disclosed by the company on the same day in Securities Times, China Securities Journal, Shanghai Securities News, Securities Daily and www.cninfo.com.cn.

This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.

12. "Report on the Audit Committee of the Board of Directors' Assessment of the Accounting Firm's Performance of Duties and Performance of Supervision Responsibilities in 2025"

Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.

For details, please refer to the "Report on the Audit Committee of the Board of Directors' Assessment of the Accounting Firm's Performance of Duties and Fulfillment of Supervisory Responsibilities in 2025" disclosed by the company on the cninfo.com.cn on the same day. This proposal has been unanimously approved at the 13th meeting of the Audit Committee of the sixth session of the Board of Directors of the company. 13. "Proposal on Re-appointment of Accounting Firm"

Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.

For details, please refer to the "Announcement on Re-appointment of the Accounting Firm" disclosed by the company on the same day in Securities Times, China Securities Journal, Shanghai Securities News, Securities Daily and www.cninfo.com.cn.

This proposal has been unanimously approved at the 13th meeting of the Audit Committee of the sixth session of the Board of Directors of the company. This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.

14. "Proposal on the General Election of the Board of Directors and Nomination of Non-Independent Director Candidates for the Seventh Board of Directors" In view of the fact that the term of the Company's sixth Board of Directors is about to expire, the company will conduct the General Election of the Board of Directors in accordance with relevant legal procedures. After the nomination committee of the sixth board of directors reviewed the candidates' qualifications, the company's board of directors agreed to nominate Mr. Li Li, Ms. Li Tan and Mr. Shan Yu as non-independent director candidates for the company's seventh board of directors, with a term of three years from the date of approval by the company's shareholders' meeting.

The directors present at the meeting voted on the above candidates item by item, and the voting results are as follows:

14.01. Nominate Mr. Li Li as a non-independent director candidate for the company’s seventh board of directors

Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.

14.02. Nominate Ms. Li Tan as a non-independent director candidate for the company’s seventh board of directors

Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.

14.03. Nominate Mr. Shan Yu as a non-independent director candidate for the company’s seventh board of directors

Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.

For details, please refer to the "Announcement on the General Election of the Board of Directors" disclosed by the company on the same day in Securities Times, China Securities Journal, Shanghai Securities News, Securities Daily and www.cninfo.com.cn. This proposal has been unanimously approved at the fifth meeting of the Nomination Committee of the sixth session of the Board of Directors of the company. This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.

15. "Proposal on the General Election of the Board of Directors and the Nomination of Independent Director Candidates for the Seventh Board of Directors" In view that the term of the Company's sixth Board of Directors is about to expire, the company will conduct the General Election of the Board of Directors in accordance with relevant legal procedures. After the nomination committee of the sixth board of directors reviewed the candidates' qualifications, the company's board of directors agreed to nominate Mr. Huang Peng, Mr. Yi Ming and Mr. Pu Hong as independent director candidates for the company's seventh board of directors, with a term of three years from the date of approval by the company's shareholders' meeting.

The directors present at the meeting voted on the above candidates item by item, and the voting results are as follows:

15.01. Nominate Mr. Huang Peng as an independent director candidate for the company’s seventh board of directors

Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.

15.02. Nominate Mr. Yi Ming as an independent director candidate for the company’s seventh board of directors

Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.

15.03. Nominate Mr. Pu Hong as an independent director candidate for the company’s seventh board of directors

Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.

For details, please refer to the "Announcement on the General Election of the Board of Directors" disclosed by the company on the same day in Securities Times, China Securities Journal, Shanghai Securities News, Securities Daily and www.cninfo.com.cn. This proposal has been unanimously approved at the fifth meeting of the Nomination Committee of the sixth session of the Board of Directors of the company. The qualifications and independence of the above-mentioned independent director candidates must be reviewed by Shenzhen Stock Exchange and other relevant departments without objection before they can be submitted to the company's shareholders' meeting for review.

16. "Proposal on the remuneration of directors and allowances for independent directors of the seventh session of the Board of Directors"

In accordance with the relevant provisions of the "Code of Corporate Governance for Listed Companies", "Measures for the Administration of Independent Directors of Listed Companies" and the "Articles of Association", and combined with the actual situation of the company, the remuneration plan for the directors of the seventh session of the board of directors and the allowance for independent directors is formulated as follows:

The remuneration of non-independent directors (including employee representative directors) who hold management functions in the company will be determined in accordance with the "Articles of Association", "Remuneration and Assessment System for Directors and Senior Management Personnel" and other relevant regulations as well as the annual operating performance assessment, including basic salary, performance remuneration and statutory social security benefits.

Independent directors have a fixed allowance of RMB 100,000 per person per year (tax included), which is paid monthly. The expenses incurred by independent directors in performing their duties shall be reimbursed by the company according to the facts.

Voting results: 0 votes in favor, 0 abstentions, and 0 votes against. (All directors abstained from voting)

This proposal has been reviewed at the fifth meeting of the Remuneration and Appraisal Committee of the sixth session of the Board of Directors of the Company. All members abstained from voting. This proposal is directly submitted to the Company's Board of Directors for review. All directors of the company abstained from voting on this proposal, which will be directly submitted to the company's 2025 annual shareholders' meeting for review.

17. "Proposal on Proposing to Convene the 2025 Annual Shareholders Meeting"

Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.

For details, please refer to the "Notice of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. on Convening the 2025 Annual Shareholders Meeting" disclosed by the company on the same day in the Securities Times, China Securities Journal, Shanghai Securities News, Securities Daily and www.cninfo.com.cn.

3. Documents available for inspection

4. Resolution of the 20th meeting of the 6th Board of Directors

5. Resolution of the 13th meeting of the Audit Committee of the 6th Board of Directors

6. Resolution of the fifth meeting of the Remuneration and Appraisal Committee of the Sixth Board of Directors

7. Resolution of the fifth meeting of the Nomination Committee of the Sixth Board of Directors

Announcement is hereby made.

Board of Directors of Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

March 31, 2026